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Prenatal infection is associated with brain structural and func-
tional abnormalities and may increase the risk for psychosis 
through a direct effect on neurodevelopment. Various infections 
may exert their effect through a proinflammatory immune re-
sponse but studies of prenatal maternal inflammatory markers 
and offspring neurodevelopment are scarce. Using the longitu-
dinal Northern Finland Birth Cohort 1986 study, we examined 
the associations of maternal prenatal C-reactive protein (CRP) 
levels with psychosis risk factors in adolescent offspring. CRP 
was measured in maternal sera collected in pregnancy. In off-
spring, school performance was measured at age 7 years, while 
school performance, psychotic experiences, and cannabis use 
were measured at age 16 years. We tested associations of CRP 
with offspring measures using regression analysis control-
ling for offspring sex, maternal education level, and prenatal 
maternal body mass index, smoking and alcohol use in preg-
nancy, place of birth, maternal psychiatric admission, paternal 
psychiatric admission, mothers age at birth, and gestational 
week of CRP sample. We also tested if adolescent cannabis 
use mediated the associations between maternal CRP and off-
spring outcomes. Controlling for covariates, maternal CRP 
was associated with academic performance at age 16  years 
(beta = .062, 95% CI = 0.036–0.088), but not with possible 
psychotic experiences at 16 years (odds ratio [OR] = 1.09, 95% 
CI = 0.96–1.24). Maternal CRP was also associated with ado-
lescent cannabis use (OR = 1.24, 95% CI = 1.07–1.43). These 
findings suggest that prenatal inflammation may influence 
later mental illness risk by affecting neurodevelopment and 
also indirectly by increasing the risk of exposure to cannabis.
Key words:  inflammation/CRP/cannabis/psychotic experiences/
birth cohort 
Introduction 
Evidence from epidemiological birth cohort and other 
longitudinal studies has linked prenatal infection and 
risk for psychotic disorders in offspring. Ecological re-
search from Finland,1 though not from Holland,2 has 
correlated higher rates of schizophrenia with presence in 
utero during an influenza epidemic. Further ecological 
evidence for an association with prenatal infection links 
the season of birth with schizophrenia.3 Importantly, 
given the methodological shortcomings of ecological 
studies, epidemiological studies with confirmed prenatal 
exposure to a range of specific infections during preg-
nancy have provided support for an association between 
prenatal infection and offspring schizophrenia.4,5 This 
has included exposure to second-trimester respiratory in-
fections6 and to specific infectious agents, such as influ-
enza,7 Toxoplasma gondii,8 and herpes simplex virus type 
2.9 Recent population-based studies from Sweden and 
Denmark have suggested that the relationship between 
prenatal infection and offspring psychosis may interact 
with other factors, including family history10,11 and peri-
pubertal trauma.12
While it is possible that specific infectious agents have 
individual pathways to illness, one explanation is that 
there is a common pathway. One possible mechanism 
is maternal immune activation.13,14 Indeed, elevated pre-
natal inflammatory markers, including C-reactive protein 
(CRP),15 and elevated prenatal cytokines have been asso-
ciated with offspring schizophrenia.16,17
Disruption of fetal development by prenatal ma-
ternal infection and immune activation is consistent 
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with the neurodevelopmental model of schizophrenia.18,19 
Consistent with this idea, maternal infection during preg-
nancy has been associated with brain structural and 
functional abnormalities relating to schizophrenia in off-
spring.20–24 Furthermore, studies have suggested that other 
adverse developmental contexts, such as maternal anemia25 
and peri-pubertal psychological trauma,12 can act along 
with prenatal infection to further increase the risk.
However, although prenatal infection has been asso-
ciated with structural and functional abnormalities in 
the brain, it remains to be seen if  it serves as an inde-
pendent risk factor for psychosis or it exerts its effects on 
a common pathway with other neurodevelopmental or 
environmental risk factors. Specifically, there is a notable 
lack of evidence on the association between prenatal in-
fection/inflammation and early markers and risk factors 
for psychosis. For example, evidence on adolescent fac-
tors such as school performance, psychotic experiences, 
and cannabis use is limited.
Finnish cohort studies have identified adolescent school 
performance as a risk factor for later schizophrenia26 and 
adolescent school performance a risk factor for cognitive 
decline.27 Maternal prenatal infection24 and maternal el-
evated cytokines28 have been associated with academic 
ability in early childhood. Evidence is lacking on whether 
this persists to the key adolescent period. Prenatal infec-
tion has also been associated with adolescent psychotic 
experiences.29 However, evidence is lacking on whether 
prenatal inflammatory markers are also associated with 
psychotic experiences. Studies utilizing the Northern 
Finland Birth Cohort 1986 (NFBC 1986)  have been 
able to observe associations between maternal prenatal 
thyroid function and offspring childhood linguistic and 
sensory development,30 intellectual and scholastic perfor-
mance,31 and inattention and hyperactivity.32 This sample, 
therefore, provides an ideal opportunity to examine the 
association between maternal immune activation in preg-
nancy and neurodevelopmental and environmental risk 
factors for psychotic disorders.
This study aims to examine whether maternal immune 
activation in pregnancy, measured by circulating CRP 
(CRP) levels, an archetypal inflammatory marker, is as-
sociated with neurodevelopmental and environmental 
risk factors for psychosis in offspring in adolescence, spe-
cifically, psychotic experiences, poorer academic perfor-
mance, and substance use.
Methods
Study Design and Setting
The NFBC 1986 is a longitudinal birth cohort, covering 
99% of births in the 2 northernmost provinces of Finland, 
Oulu and Lapland, who had an expected delivery date be-
tween July 1, 1985 and June 30, 1986, details of which have 
been described elsewhere.33,34 In brief, the cohort consisted 
of 9432 live-born children, of whom 6985 (76%) com-
pleted questionnaires35–39 at 16-year follow-up in 2001 and 
2002 (figure 1).
Measures
Collection of Maternal Sera and CRP Measurement. Maternal 
sera were available in the Finnish Maternity Cohort of 
Northern Finland Biobank Borealis for 7600 mothers of 
NFBC 1986 members. One serum sample was obtained for 
each pregnancy during the first or early second trimester of 
pregnancy. Samples were stored as one aliquot at −25°C in 
a single, centralized biorepository. High-sensitivity CRP 
was measured on the clinical chemistry analyzer Architect 
c8200 (Abbott Laboratories) using a latex immunoassay 
(Sentinel). During the course of the study, the precision 
between series expressed as the coefficient of variation 
(mean ± SD) was 5.1% ± 2.3% and the systematic error 
(bias) (mean ± SD) was −2.7% ± 7.4. Assay sensitivity was 
0.10 mg/dl. The mean CRP value was 4.2 mg/l (standard 
deviation = 6.4 mg/l). CRP values were not normally dis-
tributed and were, therefore, log-transformed and converted 
to Z-scores for ease of interpretation.
Information regarding maternal age and gestational 
week of blood draw was also collected at sampling. 
Maternal illicit drug use was also verified using urine 
drug screen at sampling.
Clinical Assessments. Participants were asked about 
smoking tobacco, alcohol, and drug use at age 16 years. 
Regarding smoking tobacco, we compared those who had 
ever smoked tobacco (n = 2882, 52.8%) to those who had 
never smoked it (n = 2581, 47.2%). Regarding alcohol, we 
compared those who had ever been drunk from alcohol 
(n  =  3417, 67.3%) to those who had never been drunk 
from it (n = 1657, 32.7%). Regarding cannabis, we com-
pared those who had ever used cannabis (n = 297, 5.7%) 
to those who had never used it (n = 4893, 94.3%).
The presence of possible psychotic experiences was 
judged using the PROD (prodromal symptoms)-screen 
(screen for prodromal symptoms) questionnaire.40We 
judged the presence of possible psychotic experiences 
when an individual endorsed possibly hearing voices 
(item 17), based on evidence that this question is most 
useful in predicting clinical psychotic experiences.41 
However, we also required that an individual endorse at 
least one other “positive” item on the PROD-screen (out 
of 10 other “positive” items) to increase the specificity 
of the measure.42 In total, 364 out of 4972 (7.3%) scored 
possible psychotic experiences using this cutoff.
Cognitive Assessments. When children were aged 7 years, 
teachers were asked if the pupil was above average, average, 
or below average. When adolescents were aged 15–16 years, 
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across academic subjects was converted into a Z-score and 
also divided into 3 equal tertiles. Factor analyses were also 
performed across performance in history, mathematics, 
physics, chemistry, biology, geography, art, and music, re-
sulting in 2 factors, one loading for academic subjects and 
the other for art and music. These factors were also trans-
formed into equal tertiles for analysis.
Other Variables.. Information was collected on body 
mass index (BMI) of the mother during pregnancy and 
on maternal education level, sex of the child, smoking 
during pregnancy, alcohol use during pregnancy, and 
birth area of the child (urban vs rural) during the preg-
nancy or at birth. For BMI, as described previously,43 
prepregnancy weight was reported on a questionnaire 
given to the mothers at their first visit to maternity health 
centers (on average at the 12th gestational week), while 
maternal height was measured in 52% of mothers during 
the same visit and self-reported by the rest.
Information was collected on substance use by ques-
tionnaire at age 16 years.
The presence of significant maternal and paternal psy-
chiatric history was assessed using data (up to 2016) from 
the Finnish Hospital Discharge Register. Parents were 
classified as having any psychiatric hospital treatment vs 
no psychiatric hospital treatment.
Statistical Analysis
Descriptive statistics (t-test and univariate regression) were 
used to characterize the association between maternal CRP 
levels and demographic factors (sex of offspring, maternal 
educational achievement, maternal BMI, place of birth 
[urban vs rural], maternal psychiatric admission, and pa-
ternal psychiatric admission), clinical factors (possible psy-
chotic experiences at age 16 years, ever smoked by 16 years, 
ever used cannabis by 16 years, and ever drunk with al-
cohol by 16 years), and cognitive factors (teacher’s impres-
sion at age 7 years and academic scores at age 16 years). 
We performed sensitivity analyses by comparing associ-
ations with maternal CRP, excluding those with CRP > 10.
Following this, the observed associations between ma-
ternal CRP and cannabis use at age 16, school standard 
at age 7, and total school performance at age 16 were fur-
ther tested using multivariate regression. These regression 
models are controlled for offspring sex, maternal edu-
cation level, maternal BMI during pregnancy, smoking 
during pregnancy, alcohol use during pregnancy, place 
of birth (urban vs rural), maternal psychiatric admission, 
paternal psychiatric admission, mothers age at birth, and 
gestational week of CRP sample. In comparing univar-
iate and multivariate analyses, only those with data on all 
covariates were used (unlike in the case of the descriptive 
statistics above).
Finally, we tested the results for possible mediation. 
As academic achievement has been associated with later 
cannabis use,44 we examined if  the CRP-cannabis as-
sociation was mediated by school performance at age 
7  years. Though debated,45 cannabis use may also be 
associated with poorer academic performance.46 We, 
therefore, examined if  the CRP-school performance at 
age 16 years association may be mediated by cannabis 
use at 16 years.
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Cannabis use at age 16 years showed a univariate asso-
ciation with elevated maternal prenatal CRP (beta = .177, 
P  =  .003, see also table  2), which remained significant 
following sensitivity analyses including only those with 
CRP < 10 (beta = .185, P = .003). The association also re-
mained significant after controlling for sex, maternal ed-
ucation level, maternal BMI during pregnancy, smoking 
during pregnancy, alcohol use during pregnancy, place of 
birth (urban vs rural), maternal psychiatric admission, 
paternal psychiatric admission, mothers age at birth, and 
gestational week of CRP sample (OR = 1.24, P = 0.003).
Statistical significance was judged significant at P < .05 
but 95% confidence intervals were also provided for the 
main outcomes to aid interpretation.
Results
Baseline Characteristics of Sample
Maternal prenatal CRP was associated with female 
sex, poor maternal education, and higher BMI (table 1) 
and with clinical and cognitive factors (table  2). The 
mean age of mothers at CRP sampling was 28.2  years 
(standard deviation = 5.4 years), while the mean gesta-
tional week of CRP sampling was 11.1 weeks (standard 
deviation = 3.6 weeks).
Associations of Prenatal CRP With Cognitive 
Performance at 7 and 16 Years
Before controlling for potential confounders, at age 
7  years, teacher-judged average (P  =  0.039) or below-
average (P = 0.009) school performance was associated 
with higher maternal prenatal CRP compared with 
above-average performance (table 2). However, this asso-
ciation did not persist in sensitivity analyses when CRP 
values >10 were excluded (change in beta coefficient from 
.056 with P = .004 to .033 with P = .112). Furthermore, 
in multivariate analysis, the observed association did 
not persist after controlling for sex, maternal education 
level, maternal BMI during pregnancy, smoking during 
pregnancy, alcohol use during pregnancy, place of birth 
(urban vs rural), maternal psychiatric admission, pa-
ternal psychiatric admission, mothers age at birth, and 
gestational week of CRP sample (odds ratio [OR] = 1.02; 
95% CI: 0.92–1.12, P = .758).
Elevated maternal prenatal CRP was associated with 
poorer academic performance at age 16 years (P = .005 for 
middle tertile and P < .001 for the lowest tertile in com-
parison with the highest tertile, see table 2). However, no 
associations were observed between the factor analysis-
derived academic factors and maternal prenatal CRP. 
The association between academic performance at age 
16 years and elevated prenatal maternal CRP persisted in 
sensitivity analyses (change in beta coefficient from .067 
with P < .001 to .044 with P = .005). The association also 
remained significant after controlling for sex, maternal ed-
ucation level, maternal BMI during pregnancy, smoking 
during pregnancy, alcohol use during pregnancy, place of 
birth (urban vs rural), maternal psychiatric admission, 
paternal psychiatric admission, mothers age at birth, and 
gestational week of CRP sample (P < .001, see table 3).
Association of Prenatal CRP With Substance Use at 
16 Years
As outlined in table 2, ever having smoked tobacco by 
age 16 years was associated with lower maternal prenatal 
CRP (P  =  .017). This association remained significant 
in sensitivity analyses after excluding those with a CRP 
level > 10 (beta = −.074, P = .009). However, the asso-
ciation was not significant in multivariate analyses, con-
trolling for sex, maternal education level, maternal BMI 
during pregnancy, smoking during pregnancy, alcohol 
use during pregnancy, place of birth (urban vs rural), 
maternal psychiatric admission, paternal psychiatric ad-
mission, mothers age at birth, and gestational week of 
CRP sample (P  =  .058, see table  3). Ever having been 
drunk with alcohol was not associated with maternal 
prenatal CRP (P = .153, see table 2).
Table 1. Maternal CRP Level by Demographic Featuresa
Factor Mean CRP (SD) P-value for Difference
Sex Male (3666, 51.4%) −0.030 (1.003) —
Female (3472, 48.6%) 0.017 (0.996) .009
Maternal education 0–8 years school (624, 10.2%) 0.198 (0.980) —
9 and 10 years school (972, 15.8%) 0.066 (0.981) .010
Vocational school/college (2788, 45.4%) −0.039 (1.014) <.001
Matriculation (1293, 21.0%) −0.081 (0.985) <.001
Commenced university (468, 7.6%) −0.057 (0.963) <.001
Body mass index Normal weight (5101, 75.4%) −0.101 (0.977) —
Underweight (525, 7.8%) −0.438 (1.082) <.001
Overweight (892, 13.2%) 0.542 (0.785) <.001
Obese (244, 3.6%) 0.932 (0.716) <.001
Place of birth Rural (1485, 20.6%) 0.06 (0.99) —
Urban (5617, 79.4%) −0.02 (1.00) .006
Maternal psychiatric admission No (6538, 91.6%) −0.001 (1.00) —
Yes (600, 8.4%) 0.02 (1.04) .653
Paternal psychiatric admission No (6281, 88.0%) −0.01 (1.00) —
Yes (857, 12.0%) 0.08 (1.00) .009
Note: CRP, C-reactive protein. 
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Cannabis use at age 16 years showed a univariate asso-
ciation with elevated maternal prenatal CRP (beta = .177, 
P  =  .003, see also table  2), which remained significant 
following sensitivity analyses including only those with 
CRP < 10 (beta = .185, P = .003). The association also re-
mained significant after controlling for sex, maternal ed-
ucation level, maternal BMI during pregnancy, smoking 
during pregnancy, alcohol use during pregnancy, place of 
birth (urban vs rural), maternal psychiatric admission, 
paternal psychiatric admission, mothers age at birth, and 
gestational week of CRP sample (OR = 1.24, P = 0.003).
Association of Prenatal CRP With Possible Psychotic 
Experiences at Age 16
Elevated prenatal maternal CRP was associated with pos-
sible psychotic experiences at age 16 years (P = .025, see 
table 2). This remained significant (beta = .118, P = .039) 
in sensitivity analyses where those with CRP > 10 were 
excluded. However, the association was no longer evi-
dent after controlling for sex, maternal education level, 
maternal BMI during pregnancy, smoking and alcohol 
use during pregnancy, place of birth (urban vs rural), 
maternal psychiatric admission, paternal psychiatric 
Table 2. Maternal CRP Level and Later Clinical Difficulties and Cognitive Performancea
Factor Mean CRP Z-score (SD) P-value for Difference
Clinical factors
 Possible psychotic experiences age 16 No (4608, 92.7%) −0.025 (0.992) —
Yes (364, 7.3%) 0.096 (0.972) .025
 Ever smoked age 16 No (2882, 52.8%) 0.026 (0.983) —
Yes (2581, 47.2%) −0.038 (0.991) .017
 Ever drunk age 16 No (1657, 32.7%) 0.013 (0.970) —
Yes (3417, 67.3%) −0.029 (1.001) .153
 Ever cannabis age 16 No (4893, 94.3%) −0.025 (0.992) —
Yes (297, 5.7%) 0.152 (0.955) .003
Cognitive performance
 Standard age 7 Above average (2345, 36.1%) −0.041 (0.988) —
Average (3475, 53.5%) 0.014 (1.004) .039
Below average (675, 10.4%) 0.073 (1.011) .009
 Academic age 16 Highest tertile (2145) −0.084 (0.990) —
Middle tertile (2243) 0.000 (0.980) .005
Lowest tertile (2421) 0.050 (1.022) <.001
 Academic factor 1 Highest tertile (2193) −0.014 (0.967) —
Middle tertile (2186) −0.009 (1.005) .877
Lowest tertile (2265) 0.006 (1.023) .517
 Academic factor 2 Highest tertile (2216) 0.007 (1.006) —
Middle tertile (2230) −0.027 (0.994) .255
Lowest tertile (2198) 0.003 (0.996) .887
Note: CRP, C-reactive protein.
aN includes all those with data available on variable.
Table 3. Associations Between CRP and Offspring Clinical and Academic Outcomes at Ages 7 and 16 Years
Outcome Samplea 
 Unadjusted Analysis  Adjusted Analysisc
Odds Ratio/Beta (95% CI)b P-value Odds Ratio/Beta (95% CI)b P-value
Possible psychotic experiences 4089 1.163 (1.03, 1.31) .014  1.093 (0.96–1.24) .176
Ever smoked age 16 4596 0.952 (0.90, 1.01) .097 0.941 (0.88–1.00) .058
Ever cannabis age 16 4267 1.223 (1.07, 1.40) .003  1.240 (1.07–1.43) .003
Standard age 7 5279 1.080 (0.99, 1.18) .096 1.016 (0.92–1.12) .758
Better academic performance age 16 5621 0.072 (−0.099, −0.046) <.001 −0.062 (−0.088, −0.036) <.001
Note: CRP, C-reactive protein.
aN includes all those with data available on all covariates (sex, maternal education level, maternal BMI during pregnancy, smoking during 
pregnancy, alcohol use during pregnancy, place of birth, maternal psychiatric admission, paternal psychiatric admission, mothers age at 
birth, and gestational week of CRP sample).
bOdds ratio for the increased risk associated with 1 standard deviation increase.
cAfter controlling for sex, maternal education level, maternal BMI during pregnancy, smoking during pregnancy, alcohol use during 
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However, there are likely to be a variety of further 
resilience and susceptibility factors that impact on the 
pathway from maternal immune activation to offspring 
outcomes.50 Interestingly, controlling for a number of 
prenatal susceptibility factors in this study did not sig-
nificantly attenuate the association between prenatal 
maternal immune activation and offspring cannabis use. 
However, a significant number of child factors may also 
play a role. Indeed, a range of other social and environ-
mental factors are likely to play a more significant role in 
adolescent cannabis use than prenatal maternal immune 
activation.
This study was not able to examine if  cannabis use is 
a mediator of any association between maternal immune 
activation and offspring psychotic disorders, due to lack 
of association between prenatal CRP and offspring PEs 
in our sample. Nevertheless, the findings reported here 
call for further investigation into potential mechanisms 
of association between prenatal CRP and adolescent 
cannabis use. The effect of inflammation on impulsivity 
and cognition could be relevant. Animal studies suggest 
that adolescent cannabis use may interact with maternal 
immune activation in a number of ways. Adolescent can-
nabinoid exposure may act synergistically with maternal 
immune activation in negatively altering the serotonin 
system.62 However, disrupted dopamine function induced 
by maternal immune activation may actually be attenu-
ated by Δ 9-tetrahydrocannabinol.63
The results of this study also give clues regarding the 
mechanism of the maternal inflammation—psychosis as-
sociation. Maternal immune activation is associated with 
a range of adverse neurodevelopmental outcomes. It is 
likely that much of the risk arises due to effects on cogni-
tive factors associated with psychosis. This would include 
those discussed above: salience networks,55 impulse con-
trol56,57 and working memory,58 and reward pathways. In 
addition, there is a need for further research to examine 
if  the association with adolescent cannabis use has an im-
pact on later risk for psychosis.
Strengths and Limitations
This study has a number of particular strengths. Firstly, 
the data were collected from the NFBC 1986. Data col-
lection from the NFBC 1986 commenced before birth 
and has continued longitudinally to the present day. The 
rate of follow-up on the cohort was good with over 4000 
individuals available. This strengthens the significance 
of the observed associations between maternal immune 
activation and the neurodevelopmental and behavioral 
outcomes studied. Secondly, the study controlled for a 
range of important potential covariates, including sex 
of the offspring, maternal education, tobacco and al-
cohol use during pregnancy, maternal BMI during preg-
nancy, place of birth, maternal psychiatric admission, 
paternal psychiatric admission, mothers age at birth, and 
admission, mothers age at birth, and gestational week 
of CRP sample (unadjusted OR = 1.16, 95% CI: 1.03–
1.31, P = .014; adjusted OR = 1.09; 95% CI: 0.96–1.24, 
P = .176, see table 3).
Results for Mediation Analyses
There was minimal evidence that the association between 
prenatal maternal CRP and cannabis use at 16  years 
was mediated by school performance at age 7 years (OR 
changed from 1.24, P = .003 to 1.20, P = .014). The Sobel 
test found no indirect effect (coefficient < .001, P = .362) 
in the context of a low direct effect (coefficient =  .005, 
P = .246) and suggested that only 1.9% of the observed 
(low) effect was mediated by school performance at 
7 years.
There was some evidence for mediation of the associa-
tion between prenatal maternal CRP and school perfor-
mance at 16  years by cannabis use (beta changed from 
−.062, P < .001 to −.047, P = .001). The Sobel test ob-
served an indirect effect of −.005 (P = .007) in the con-
text of a direct effect of −.011 (P < .005), suggesting that 
5.8% of the observed effect was mediated by cannabis.
Discussion
This study has found that a marker of maternal im-
mune activation in pregnancy is associated with adoles-
cent neurodevelopmental and behavioral risk factors for 
psychosis, including cannabis use and academic perfor-
mance, even after controlling for important covariates.
Prenatal maternal infection has been clearly associated 
with risk for schizophrenia in offspring.4,5 It has also been 
associated with functional and structural abnormalities 
relating to schizophrenia in offspring.4,21,22 However, to 
date, there has been minimal evidence on a possible link 
between prenatal immune activation and adolescent risk 
factors for schizophrenia, such as adolescent academic 
performance, psychotic experiences, and cannabis use.
Maternal Immune Activation and Child and Adolescent 
Outcomes
The results here suggest that maternal immune activation 
during pregnancy is associated with neurodevelopmental 
and behavioral features, including poorer academic at-
tainment and increased cannabis use. This is consistent 
with findings from animal studies that prenatal im-
mune activation results in changes in behavior and cen-
tral nervous system structure and function.47As outlined 
above, one possible biological mechanism is the effect of 
proinflammatory cytokines.16,17 Systemic inflammatory 
cytokines communicate with the brain.48 Maternal im-
mune activation and resultant cytokines can impact on 
neurogenesis, migration, differentiation, and apoptosis, 
leading to diverse adverse outcomes.49
Though markers of maternal immune activation have 
been previously associated with psychotic disorders,15 it is 
unsurprising that the univariate association of a marker 
of maternal inflammation and possible psychotic ex-
periences did not survive controlling for key covariates. 
Maternal immune activation results in heterogeneous 
outcomes for offspring, with varying levels of resilience 
and susceptibility to a wide range of outcomes.50 The 
findings here must be viewed in this context with other 
prenatal and childhood factors likely interacting with the 
timing and intensity of maternal immune activation in 
pregnancy in its association with adolescent outcomes. In 
the case of possible psychotic experiences, controlling for 
a number of these prenatal factors (eg, maternal BMI, 
maternal substance use, and parental psychiatric history) 
eliminated any evidence for an association. Additionally, 
the observed maternal CRP levels in those who later 
have possible psychotic experiences were only marginally 
higher than in those who did not have these experiences. 
This may reflect that adolescent psychotic experiences are 
relatively common51 and that only a minority of adoles-
cents who describe psychotic experiences later develop a 
psychotic disorder.52 Psychotic experiences in adolescence 
also appear to be a heterogeneous group, including many 
who develop nonpsychotic disorders or no disorders 
at all.53 Psychotic experiences are a relatively “softer” 
neurodevelopmental feature compared with psychotic 
disorders.
The finding of an association between maternal im-
mune activation and adolescent cannabis use is perhaps 
the most surprising. It adds to existing evidence that can-
nabis use and predisposition to psychosis have a shared 
genetic and environmental basis.54 The mechanism of the 
association between maternal immune activation and 
adolescent cannabis use may involve circuitry involved 
in specific cognitive functions, particularly as our study 
suggests that the impact was not mediated through an ef-
fect on broader cognitive function (observed in academic 
performance). Spann et al found that maternal immune 
activation during the third trimester was associated with 
neonatal functional connectivity of  the salience network 
in fetal and toddler behavior.55 Increased markers of  ma-
ternal immune activation have been associated with lower 
impulse control and associated brain structural findings 
at 24 months of age.56,57 Maternal immune activation has 
also been associated with poorer working memory at 
2 years.58 This increased impulsivity and problems with 
working memory may persist to adolescence, increasing 
the risk for cannabis use in this group exposed to ma-
ternal immune activation. Maternal immune activation 
in pregnancy has also been associated with dopaminergic 
maldevelopment in animal models, leading to functional 
abnormalities implicated in schizophrenia.59,60 Given the 
role of  the dopaminergic neurons in the reward system,61 
this may also be a mechanism through which maternal 
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However, there are likely to be a variety of further 
resilience and susceptibility factors that impact on the 
pathway from maternal immune activation to offspring 
outcomes.50 Interestingly, controlling for a number of 
prenatal susceptibility factors in this study did not sig-
nificantly attenuate the association between prenatal 
maternal immune activation and offspring cannabis use. 
However, a significant number of child factors may also 
play a role. Indeed, a range of other social and environ-
mental factors are likely to play a more significant role in 
adolescent cannabis use than prenatal maternal immune 
activation.
This study was not able to examine if  cannabis use is 
a mediator of any association between maternal immune 
activation and offspring psychotic disorders, due to lack 
of association between prenatal CRP and offspring PEs 
in our sample. Nevertheless, the findings reported here 
call for further investigation into potential mechanisms 
of association between prenatal CRP and adolescent 
cannabis use. The effect of inflammation on impulsivity 
and cognition could be relevant. Animal studies suggest 
that adolescent cannabis use may interact with maternal 
immune activation in a number of ways. Adolescent can-
nabinoid exposure may act synergistically with maternal 
immune activation in negatively altering the serotonin 
system.62 However, disrupted dopamine function induced 
by maternal immune activation may actually be attenu-
ated by Δ 9-tetrahydrocannabinol.63
The results of this study also give clues regarding the 
mechanism of the maternal inflammation—psychosis as-
sociation. Maternal immune activation is associated with 
a range of adverse neurodevelopmental outcomes. It is 
likely that much of the risk arises due to effects on cogni-
tive factors associated with psychosis. This would include 
those discussed above: salience networks,55 impulse con-
trol56,57 and working memory,58 and reward pathways. In 
addition, there is a need for further research to examine 
if  the association with adolescent cannabis use has an im-
pact on later risk for psychosis.
Strengths and Limitations
This study has a number of particular strengths. Firstly, 
the data were collected from the NFBC 1986. Data col-
lection from the NFBC 1986 commenced before birth 
and has continued longitudinally to the present day. The 
rate of follow-up on the cohort was good with over 4000 
individuals available. This strengthens the significance 
of the observed associations between maternal immune 
activation and the neurodevelopmental and behavioral 
outcomes studied. Secondly, the study controlled for a 
range of important potential covariates, including sex 
of the offspring, maternal education, tobacco and al-
cohol use during pregnancy, maternal BMI during preg-
nancy, place of birth, maternal psychiatric admission, 
paternal psychiatric admission, mothers age at birth, and 
gestational week of CRP sample. Self-reported illicit sub-
stance use in pregnancy was further validated using urine 
drug screening.
The study would have benefitted from a broader panel 
of markers of maternal immune activation (eg, inter-
leukin-6 levels during pregnancy) and from maternal 
illness history factors. However, CRP is a good general 
measure of immune activation, especially considering 
we controlled for important factors that can influence 
this (eg, BMI). Future studies could add to this work by 
examining other markers of immune activation. A second 
limitation is that many of the adolescent measures are 
self-reported (particularly cannabis use and possible psy-
chotic experiences). Ideally, these would have been meas-
ured through laboratory study (cannabis use) and clinical 
interview (possible psychotic experiences). Given the 
numbers included in the study, unfortunately, self-report 
was only possible. While self-report of psychotic experi-
ences is a significant limitation, the item was strengthened 
by requiring both that the person reported the hearing 
voices item on the PROD-screen and a further additional 
“positive” score item. Self-reported cannabis use was also 
low (5.7%) in this study. This likely reflects cultural fac-
tors with markedly higher levels of alcohol misuse (67% 
of the sample reported having been drunk on alcohol). 
The prevalence is likely now higher and this may impact 
on observed associations. Academic results were a more 
objective measure and these also indicated an association 
with maternal immune activation. A further limitation of 
the study is the low proportion who were using cannabis, 
limiting generalizability to other settings where cannabis 
use is more common.
Further Research
Future research on the association between maternal im-
mune activation and psychosis could consider a broader 
range of maternal immune markers. In addition, it is impor-
tant to consider how the associations with cannabis use and 
academic performance may relate to later risk for psychotic 
disorders. We lacked sufficient numbers to consider this 
question but it would be possible in a larger cohort. A larger 
cohort could also further explore factors influencing resil-
ience and susceptibility to maternal immune activation that 
were not considered in this study. There is also considerable 
scope for animal model studies to further explore the neuro-
chemical and behavioral effects of offspring substance use 
on maternal immune activation, integrating evidence on 
specific neuroreceptors and brain regions.
Conclusions
Building on the literature suggesting links between pre-
natal maternal infection, immune activation, and adult 
schizophrenia, using a prospective birth cohort, we re-
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with known risk factors for schizophrenia and psychotic 
disorders, notably adolescent academic performance and 
cannabis use. These findings add to our understanding of 
how prenatal maternal immune activation may be associ-
ated with psychotic disorders in offspring.
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